niacinamide and Dermatitis Medicamentosa studies

nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.

Research Excerpts

Excerpt	Relevance	Reference
"In a multicenter phase-II-DeCOG study (NCT00623402) in 10 dermato-oncology centers, 55 patients with metastatic melanoma received a combination of sorafenib (2 x 400 mg/day orally) and pegylated interferon alpha-2b (3 μg/kg body weight 1 x/week subcutaneously)."	9.17	Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha-2b in metastatic melanoma (phase II DeCOG trial). ( Degen, A; Egberts, F; Garbe, C; Gutzmer, R; Hauschild, A; Kilian, K; Poppe, LM; Trefzer, U; Ugurel, S; Weichenthal, M, 2013)
" Toxicity was manageable and as previously described for sorafenib, including hypertension and skin rash."	9.17	Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. ( Chapman, R; Dowlati, A; Fu, P; Lavertu, P; Nagaiah, G; Remick, SC; Savvides, P; Wasman, J; Wright, JJ, 2013)
" Sorafenib, a multikinase inhibitor of VEGFR-2/-3, PDGFR-beta, B-Raf, and C-Raf, has shown to be active in preclinical models of cholangiocarcinoma."	9.14	Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. ( Aitini, E; Bengala, C; Bertolini, F; Boni, C; Conte, P; Dealis, C; Del Giovane, C; Depenni, R; Fontana, A; Luppi, G; Malavasi, N; Zironi, S, 2010)
"Sorafenib, a multi-kinase inhibitor with anti-angiogenic activity, was recently approved for the treatment of advanced hepatocellular carcinoma (HCC)."	9.14	Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. ( Chen, PJ; Cheng, AL; Ding, YH; Hsu, C; Hsu, CH; Lin, ZZ; Shao, YY; Shen, YC, 2010)
"Ninety-nine patients with psoriasis were treated topically with 6-aminonicotinamide (6-AN) in four years."	9.04	Topical 6-aminonicotinamide plus oral niacinamide therapy for psoriasis. ( Zackheim, HS, 1978)
"As a group of European nurses familiar with treating patients with renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC) using targeted/chemo- therapies, we aimed to review strategies for managing adverse events (AEs) associated with one targeted therapy, sorafenib."	8.88	Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group. ( Boers-Doets, C; Chrysou, M; Edmonds, K; Hull, D; Koldenhof, J; Molassiotis, A; Spencer-Shaw, A, 2012)
"Sorafenib is the standard first-line therapy for hepatocellular carcinoma (HCC) and probably ectopic hepatocellular carcinoma (EHCC) as well."	7.83	A case report: delayed high fever and maculopapules during Sorafenib treatment of ectopic hepatocellular carcinoma. ( Chen, X; Cui, T; Diao, X; Huang, S; Sun, J, 2016)
" Here, we report a pharmacokinetic interaction between sorafenib and the CYP3A4 inducer prednisolone in a patient with hepatocellular carcinoma (HCC)."	7.79	Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma. ( Fujiyama, Y; Hira, D; Morita, SY; Noda, S; Shioya, M; Terada, T, 2013)
"To investigate the link between the antitumor efficacy of sorafenib and its cutaneous side effects in advanced hepatocellular carcinoma (HCC)."	7.78	[Relationship between sorafenib-associated hand-food skin reaction and efficacy in treatment of advanced hepatocellular carcinoma]. ( He, X; Hu, BS; Li, Y; Lu, LG; Luo, XN; Shao, PJ; Yu, XY, 2012)
"The authors present a case of erythema multiforme-like drug reaction to the multikinase inhibitor sorafenib."	7.77	Erythema multiforme-like drug reaction to sorafenib. ( Farley-Loftus, R; Lewin, J; Pomeranz, MK, 2011)
"Sorafenib is an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases and has led to a longer median overall survival (OS) time and time to progression (TTP) in patients with advanced hepatocellular carcinoma (HCC)."	7.76	Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. ( Addeo, R; Caraglia, M; Colucci, G; Del Prete, S; Frezza, AM; Giuliani, F; Montella, L; Rizzo, S; Russo, A; Santini, D; Tonini, G; Venditti, O; Vincenzi, B, 2010)
"Sorafenib is the only drug that has shown a survival benefit in patients with hepatocellular carcinoma in randomized Phase 3 trials."	7.76	Sorafenib for recurrent hepatocellular carcinoma after liver transplantation. ( Ahn, CS; Hwang, S; Kang, YK; Kim, KH; Kim, TW; Lee, HC; Lee, SG; Moon, DB; Ryoo, BY; Ryu, MH; Suh, DJ; Yoon, DH, 2010)
" One such therapy, a tyrosine kinase inhibitor (sorafenib) is now used to treat patients with advanced hepatocellular carcinoma (HCC) and metastatic renal cell carcinoma."	7.76	Managing patients receiving sorafenib for advanced hepatocellular carcinoma: a case study. ( Armstrong, C; Hull, D, 2010)
"These data suggest that there could be an association between sorafenib therapy and the development of cutaneous SCC and inflammation of AK."	7.75	Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. ( Dubauskas, Z; Hwu, P; Jonasch, E; Kunishige, J; Prieto, VG; Tannir, NM, 2009)
"Sorafenib treatment was effective in two patients who achieved a partial response and a continuous stable disease with duration of 24."	6.78	Sorafenib in patients with refractory or recurrent multiple myeloma. ( Goldschmidt, H; Gütgemann, I; Hose, D; Moehler, T; Neben, K; Raab, MS; Schmidt-Wolf, IG; Witzens-Harig, M; Yordanova, A, 2013)
"Sorafenib is a chemotherapeutic agent primarily used to treat metastatic renal cell carcinoma."	5.37	Chloracne-like drug eruption associated with sorafenib. ( Hughes, M; Pickert, A; Wells, M, 2011)
"Hand-foot syndrome is one of the more frequent toxicity related to sorafenib."	5.35	[Hand-foot syndrome and sorafenib]. ( Desmedt, E; Digue, L; Milano, G; Mortier, L; Ravaud, A, 2009)
"Sorafenib is the first anti-angiogenic agent to demonstrate activity in RMSGC patients, particularly in some histotypes such as HG-MEC, SDC and adenocarcinoma, NOS."	5.22	A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact. ( Alfieri, S; Bergamini, C; Bossi, P; Civelli, E; Cortelazzi, B; Dagrada, GP; Granata, R; Imbimbo, M; Licitra, L; Lo Vullo, S; Locati, LD; Mariani, L; Mirabile, A; Morosi, C; Orlandi, E; Perrone, F; Pilotti, S; Quattrone, P; Resteghini, C; Saibene, G, 2016)
"In a multicenter phase-II-DeCOG study (NCT00623402) in 10 dermato-oncology centers, 55 patients with metastatic melanoma received a combination of sorafenib (2 x 400 mg/day orally) and pegylated interferon alpha-2b (3 μg/kg body weight 1 x/week subcutaneously)."	5.17	Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha-2b in metastatic melanoma (phase II DeCOG trial). ( Degen, A; Egberts, F; Garbe, C; Gutzmer, R; Hauschild, A; Kilian, K; Poppe, LM; Trefzer, U; Ugurel, S; Weichenthal, M, 2013)
" Toxicity was manageable and as previously described for sorafenib, including hypertension and skin rash."	5.17	Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. ( Chapman, R; Dowlati, A; Fu, P; Lavertu, P; Nagaiah, G; Remick, SC; Savvides, P; Wasman, J; Wright, JJ, 2013)
"Sorafenib, a multi-kinase inhibitor with anti-angiogenic activity, was recently approved for the treatment of advanced hepatocellular carcinoma (HCC)."	5.14	Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. ( Chen, PJ; Cheng, AL; Ding, YH; Hsu, C; Hsu, CH; Lin, ZZ; Shao, YY; Shen, YC, 2010)
" Sorafenib, a multikinase inhibitor of VEGFR-2/-3, PDGFR-beta, B-Raf, and C-Raf, has shown to be active in preclinical models of cholangiocarcinoma."	5.14	Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. ( Aitini, E; Bengala, C; Bertolini, F; Boni, C; Conte, P; Dealis, C; Del Giovane, C; Depenni, R; Fontana, A; Luppi, G; Malavasi, N; Zironi, S, 2010)
"Ninety-nine patients with psoriasis were treated topically with 6-aminonicotinamide (6-AN) in four years."	5.04	Topical 6-aminonicotinamide plus oral niacinamide therapy for psoriasis. ( Zackheim, HS, 1978)
"As a group of European nurses familiar with treating patients with renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC) using targeted/chemo- therapies, we aimed to review strategies for managing adverse events (AEs) associated with one targeted therapy, sorafenib."	4.88	Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group. ( Boers-Doets, C; Chrysou, M; Edmonds, K; Hull, D; Koldenhof, J; Molassiotis, A; Spencer-Shaw, A, 2012)
" Our article focuses on the palmoplantar erythrodysesthesia syndrome, designated also as the hand-foot skin reaction (HFSR), which most frequently occurs in patients treated with TKI sorafenib and sunitinib."	4.86	[Hand-foot syndrome after administration of tyrosinkinase inhibitors]. ( Bednaríková, D; Kocák, I, 2010)
"Sorafenib is a multitargeted kinase inhibitor currently used in the treatment of advanced hepatocellular carcinoma (HCC)."	3.85	Nodular-cystic eruption in course of sorafenib administration for hepatocarcinoma: An unconventional skin reaction requiring unconventional treatment. ( Borgia, F; Cannavò, SP; Franzè, MS; Lentini, M; Saitta, C; Vaccaro, M, 2017)
"Sorafenib is the standard first-line therapy for hepatocellular carcinoma (HCC) and probably ectopic hepatocellular carcinoma (EHCC) as well."	3.83	A case report: delayed high fever and maculopapules during Sorafenib treatment of ectopic hepatocellular carcinoma. ( Chen, X; Cui, T; Diao, X; Huang, S; Sun, J, 2016)
" This case report discusses an atypical presentation of the hand-foot syndrome in one patient treated with sorafenib."	3.80	Hand, foot and scrotal blisters in a patient with cancer receiving oral chemotherapy. ( Bella, A; Guerra, JR; Lolo, D; Suelves, AM, 2014)
" Here, we report a pharmacokinetic interaction between sorafenib and the CYP3A4 inducer prednisolone in a patient with hepatocellular carcinoma (HCC)."	3.79	Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma. ( Fujiyama, Y; Hira, D; Morita, SY; Noda, S; Shioya, M; Terada, T, 2013)
"To investigate the link between the antitumor efficacy of sorafenib and its cutaneous side effects in advanced hepatocellular carcinoma (HCC)."	3.78	[Relationship between sorafenib-associated hand-food skin reaction and efficacy in treatment of advanced hepatocellular carcinoma]. ( He, X; Hu, BS; Li, Y; Lu, LG; Luo, XN; Shao, PJ; Yu, XY, 2012)
"The authors present a case of erythema multiforme-like drug reaction to the multikinase inhibitor sorafenib."	3.77	Erythema multiforme-like drug reaction to sorafenib. ( Farley-Loftus, R; Lewin, J; Pomeranz, MK, 2011)
"Sorafenib is a new drug, multikinase inhibitor, which has been recently approved for the treatment of metastatic renal cell carcinoma and hepatocellular carcinoma."	3.77	Severe sorafenib-induced hand-foot skin reaction. ( Betlloch, I; Cuesta, L; Latorre, N; Monteagudo, A; Toledo, F, 2011)
" One such therapy, a tyrosine kinase inhibitor (sorafenib) is now used to treat patients with advanced hepatocellular carcinoma (HCC) and metastatic renal cell carcinoma."	3.76	Managing patients receiving sorafenib for advanced hepatocellular carcinoma: a case study. ( Armstrong, C; Hull, D, 2010)
"Sorafenib is the only drug that has shown a survival benefit in patients with hepatocellular carcinoma in randomized Phase 3 trials."	3.76	Sorafenib for recurrent hepatocellular carcinoma after liver transplantation. ( Ahn, CS; Hwang, S; Kang, YK; Kim, KH; Kim, TW; Lee, HC; Lee, SG; Moon, DB; Ryoo, BY; Ryu, MH; Suh, DJ; Yoon, DH, 2010)
"Sorafenib is an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases and has led to a longer median overall survival (OS) time and time to progression (TTP) in patients with advanced hepatocellular carcinoma (HCC)."	3.76	Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. ( Addeo, R; Caraglia, M; Colucci, G; Del Prete, S; Frezza, AM; Giuliani, F; Montella, L; Rizzo, S; Russo, A; Santini, D; Tonini, G; Venditti, O; Vincenzi, B, 2010)
"Retrospectively, we reviewed medical records of patients receiving multitargeted kinase inhibitors, including 109 patients on sorafenib for the treatment of renal cell carcinoma or hepatocellular carcinoma and 119 patients receiving sunitinib for treatment of renal cell carcinoma or a gastrointestinal stromal tumour."	3.75	Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. ( Chang, SE; Choi, JH; Kang, YK; Koh, JK; Lee, JL; Lee, MW; Lee, WJ; Moon, KC, 2009)
"Sorafenib, a multitargeted kinase inhibitor used for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinomas, received FDA approval in 2005."	3.75	Localized dyskeratotic plaque with milia associated with sorafenib. ( Burkemper, NM; Chappell, JA; Semchyshyn, N, 2009)
"These data suggest that there could be an association between sorafenib therapy and the development of cutaneous SCC and inflammation of AK."	3.75	Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. ( Dubauskas, Z; Hwu, P; Jonasch, E; Kunishige, J; Prieto, VG; Tannir, NM, 2009)
"Effective adverse event (AE) management is critical to maintaining patients on anticancer therapies."	2.80	Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer. ( Ando, Y; Bonichon, F; Brose, MS; Chung, J; Fassnacht, M; Fugazzola, L; Gao, M; Hadjieva, T; Hasegawa, Y; Kappeler, C; Meinhardt, G; Park, DJ; Schlumberger, M; Shi, Y; Shong, YK; Smit, JW; Worden, F, 2015)
"Sorafenib treatment was effective in two patients who achieved a partial response and a continuous stable disease with duration of 24."	2.78	Sorafenib in patients with refractory or recurrent multiple myeloma. ( Goldschmidt, H; Gütgemann, I; Hose, D; Moehler, T; Neben, K; Raab, MS; Schmidt-Wolf, IG; Witzens-Harig, M; Yordanova, A, 2013)
"Eighty-five patients with renal cell cancer treated between November 1, 2003, and February 28, 2005."	2.73	Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. ( Autier, J; Escudier, B; Robert, C; Spatz, A; Wechsler, J, 2008)
") on a continuous dosing schedule."	2.73	Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. ( Akaza, H; Murai, M; Naito, S; Nakajima, K; Tsukamoto, T, 2007)
"As new antiangiogenic therapies have been introduced and added to the therapeutic arsenal against various types of cancer, previously unknown adverse effects have been detected."	2.50	Antiangiogenic agents and the skin: cutaneous adverse effects of sorafenib, sunitinib, and bevacizumab. ( Ara, M; Pastushenko, E, 2014)
" This has raised challenges in the management of adverse events (AEs) associated with the six targeted agents approved in RCC-sorafenib, sunitinib, pazopanib, bevacizumab (in combination with interferon alpha), temsirolimus, and everolimus."	2.48	Targeted therapies for renal cell carcinoma: review of adverse event management strategies. ( Eisen, T; Escudier, B; Izzedine, H; Mulders, P; Pyle, L; Robert, C; Sternberg, CN; Zbinden, S, 2012)
"While new anticancer angiogenesis inhibitors present a well-tolerated safety profile, they are not without adverse events."	2.47	[Dermatologic side effects induced by new angiogenesis inhibitors]. ( Chevreau, C; Cottura, E; Garrido-Stowhas, I; Sibaud, V, 2011)
"The Barcelona Clinic Liver Cancer staging classification system is a clinically useful algorithm for the management of patients with hepatocellular carcinoma."	2.46	Review article: the management of hepatocellular carcinoma. ( Cabrera, R; Nelson, DR, 2010)
" This article presents a case study to illustrate side-effect management strategies for patients receiving MKIs for the treatment of advanced renal cell carcinoma."	2.45	Management of vascular endothelial growth factor and multikinase inhibitor side effects. ( Wood, LS, 2009)
"Previously, treatment of renal cancer was limited to nephrectomy or immunotherapy (interleukin or interferon-alpha), which was effective in a small subset of patients but often was accompanied by severe side effects."	2.44	Sorafenib: a promising new targeted therapy for renal cell carcinoma. ( Manchen, B; Wood, LS, 2007)
"Sorafenib was well tolerated at the RDP, and induced sustained disease stabilization, particularly in patients with skin toxicity/diarrhoea."	2.43	Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome? ( Awada, A; Brueckner, A; Christensen, O; Clark, JW; Hirte, H; Hofstra, E; Piccart, P; Schwartz, B; Seeber, S; Strumberg, D; Voliotis, D, 2006)
"Sorafenib is a multi-kinase inhibitor for treating advanced hepatocellular and renal cell carcinomas by targeting various types of receptors and signaling molecules, including vascular endothelial growth factor receptors, platelet-derived growth factor receptor, and Raf-1."	1.46	Sorafenib stimulates human skin type mast cell degranulation and maturation. ( Kira, Y; Mizukami, Y; Sugawara, K; Tsuruta, D, 2017)
" The dosage was temporarily reduced in only two patients, and oral steroids were added in four."	1.43	Widespread morbilliform rash due to sorafenib or vemurafenib treatment for advanced cancer; experience of a tertiary dermato-oncology clinic. ( Amitay-Laish, I; Didkovsky, E; Hendler, D; Hodak, E; Lotem, M; Merims, S; Ollech, A; Popovtzer, A; Stemmer, SM, 2016)
"Sorafenib is a multikinase inhibitor FDA-approved for the treatment of advanced renal cell and hepatocellular carcinoma."	1.39	Sorafenib induced eruptive melanocytic lesions. ( Aronson, P; Uhlenhake, EE; Watson, AC, 2013)
"Sorafenib is a chemotherapeutic agent primarily used to treat metastatic renal cell carcinoma."	1.37	Chloracne-like drug eruption associated with sorafenib. ( Hughes, M; Pickert, A; Wells, M, 2011)
"Sorafenib is a multikinase inhibitor that blocks tumor cell proliferation and angiogenesis and is used for the treatment of advanced renal cell carcinoma, unresectable hepatocellular carcinoma, and other solid tumors."	1.36	Sorafenib-induced psoriasiform eruption in a patient with metastatic thyroid carcinoma. ( Chon, SY; Diamantis, ML, 2010)
"Hand-foot syndrome is one of the more frequent toxicity related to sorafenib."	1.35	[Hand-foot syndrome and sorafenib]. ( Desmedt, E; Digue, L; Milano, G; Mortier, L; Ravaud, A, 2009)
"Sorafenib is a targeted drug specifically engineered to inhibit Raf serine/threonine kinases, which are part of the reticular activating system (RAS) oncogene pathway."	1.35	Cutaneous drug eruptions induced by sorafenib: a case series. ( Kung, EF; Maddox, JS; Petronic-Rosic, V; Sethi, A, 2008)
"A woman diagnosed of a renal cell carcinoma in 1989 had a metastatic kidney cancer localised in subcutaneous nodules, gut and lung in 2007."	1.35	Generalised erythematous skin eruptions induced by sorafenib: cutaneous toxicity and treatment outcome. ( Borrás-Blasco, J; Casterá, ME; Galán Brotons, A; Rosique-Robles, JD; Vicent Verge, JM, 2008)
" We report the development of localized palmar-plantar epidermal hyperplasia, a rare but significant cutaneous adverse event from sorafenib therapy."	1.34	Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib. ( Beldner, M; Burges, GE; Chaudhary, UB; Dewaay, D; Jacobson, M; Maize, JC, 2007)
"A 11-year-old girl suffering from grand mal epilepsy underwent antiepileptic therapy with carbamazepine (600 mg/daily)."	1.30	[Dose-dependent pellagroid skin reaction caused by carbamazepine]. ( Heyer, G; Schell, H; Simon, M, 1998)

Research

Studies (87)

Authors

Clinical Trials (7)

Trial Overview

Trial Outcomes

AUC(0-12h),ss (Area Under the Concentration Time Curve From Time 0 to 12 Hours at Steady State)

Timeframe	Studies, this research(%)	All Research%
pre-1990	5 (5.75)	18.7374
1990's	1 (1.15)	18.2507
2000's	29 (33.33)	29.6817
2010's	52 (59.77)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Borgia, F	1
Saitta, C	1
Vaccaro, M	1
Franzè, MS	1
Lentini, M	1
Cannavò, SP	1
Mizukami, Y	1
Sugawara, K	1
Kira, Y	1
Tsuruta, D	1
Ochi, M	1
Kamoshida, T	1
Ohkawara, A	1
Ohkawara, H	1
Kakinoki, N	1
Hirai, S	1
Yanaka, A	1
Yordanova, A	1
Hose, D	1
Neben, K	1
Witzens-Harig, M	1
Gütgemann, I	1
Raab, MS	1
Moehler, T	1
Goldschmidt, H	1
Schmidt-Wolf, IG	1
Noda, S	1
Shioya, M	1
Hira, D	1
Fujiyama, Y	1
Morita, SY	1
Terada, T	1
Degen, A	2
Weichenthal, M	1
Ugurel, S	1
Trefzer, U	1
Kilian, K	1
Garbe, C	1
Egberts, F	1
Poppe, LM	1
Hauschild, A	1
Gutzmer, R	2
Uhlenhake, EE	1
Watson, AC	1
Aronson, P	1
Derbel Miled, O	1
Dionne, C	1
Terret, C	1
Segura-Ferlay, C	1
Flechon, A	1
Neidhart, EM	1
Negrier, S	1
Droz, JP	1
Pichler, M	1
Carriere, C	1
Mazzoleni, G	1
Kluge, R	1
Eisendle, K	1
Eberst, E	1
Rigau, V	1
Pageaux, GP	1
Guillot, B	1
Kluger, N	1
Abdel-Rahman, O	1
Fouad, M	1
Ara, M	1
Pastushenko, E	1
Guerra, JR	1
Suelves, AM	1
Bella, A	1
Lolo, D	1
İlknur, T	1
Akarsu, S	1
Çarsanbali, S	1
Lebe, B	1
Fetil, E	1
Batalla, A	1
Menéndez, L	1
Blay, P	1
Curto, JR	1
Worden, F	1
Fassnacht, M	1
Shi, Y	1
Hadjieva, T	1
Bonichon, F	1
Gao, M	1
Fugazzola, L	1
Ando, Y	1
Hasegawa, Y	1
Park, DJ	1
Shong, YK	1
Smit, JW	1
Chung, J	1
Kappeler, C	1
Meinhardt, G	1
Schlumberger, M	1
Brose, MS	1
Pichard, DC	1
Cardones, AR	1
Chu, EY	1
Dahut, WL	1
Kong, HH	4
Ollech, A	1
Stemmer, SM	1
Merims, S	1
Lotem, M	1
Popovtzer, A	1
Hendler, D	1
Hodak, E	1
Didkovsky, E	1
Amitay-Laish, I	1
Farris, P	1
Zeichner, J	1
Berson, D	1
Cui, T	1
Diao, X	1
Chen, X	1
Huang, S	1
Sun, J	1
Locati, LD	1
Perrone, F	1
Cortelazzi, B	1
Bergamini, C	1
Bossi, P	1
Civelli, E	1
Morosi, C	1
Lo Vullo, S	1
Imbimbo, M	1
Quattrone, P	1
Dagrada, GP	1
Granata, R	1
Resteghini, C	1
Mirabile, A	1
Alfieri, S	1
Orlandi, E	1
Mariani, L	1
Saibene, G	1
Pilotti, S	1
Licitra, L	1
Sibaud, V	3
Chanco Turner, ML	1
Fojo, T	1
Hornyak, TJ	1
Chevreau, C	3
Autier, J	2
Escudier, B	2
Wechsler, J	2
Spatz, A	2
Robert, C	5
Cicek, D	1
Kandi, B	1
Dagli, FA	1
Karaoglu, A	1
Haligur, BD	1
Galán Brotons, A	1
Borrás-Blasco, J	1
Rosique-Robles, JD	1
Vicent Verge, JM	1
Casterá, ME	1
Maddox, JS	1
Kung, EF	1
Petronic-Rosic, V	2
Sethi, A	1
Wolber, C	1
Udvardi, A	1
Tatzreiter, G	1
Schneeberger, A	1
Volc-Platzer, B	1
Bukowski, RM	1
Dubauskas, Z	1
Kunishige, J	1
Prieto, VG	1
Jonasch, E	1
Hwu, P	1
Tannir, NM	1
Milano, G	1
Mortier, L	1
Digue, L	1
Desmedt, E	1
Ravaud, A	1
Feltes, RA	1
Feito Rodríguez, M	1
González-Beato, MJ	1
Chappell, JA	1
Burkemper, NM	1
Semchyshyn, N	1
Lee, WJ	1
Lee, JL	1
Chang, SE	1
Lee, MW	1
Kang, YK	2
Choi, JH	1
Moon, KC	1
Koh, JK	1
Turner, ML	1
La Vine, DB	1
Coleman, TA	1
Davis, CH	1
Carbonell, CE	1
Davis, WB	1
Echeverría, B	1
Llombart, B	1
Botella-Estrada, R	1
Guillén, C	1
Lipworth, AD	1
Zhu, AX	1
Cabrera, R	1
Nelson, DR	1
Bengala, C	1
Bertolini, F	1
Malavasi, N	1
Boni, C	1
Aitini, E	1
Dealis, C	1
Zironi, S	1
Depenni, R	1
Fontana, A	1
Del Giovane, C	1
Luppi, G	1
Conte, P	1
Wood, LS	2
Jain, L	1
Gardner, ER	1
Figg, WD	1
Chernick, MS	1
Vincenzi, B	1
Santini, D	1
Russo, A	1
Addeo, R	1
Giuliani, F	1
Montella, L	1
Rizzo, S	1
Venditti, O	1
Frezza, AM	1
Caraglia, M	1
Colucci, G	1
Del Prete, S	1
Tonini, G	1
Diamantis, ML	1
Chon, SY	1
Hsu, CH	1
Shen, YC	1
Lin, ZZ	1
Chen, PJ	1
Shao, YY	1
Ding, YH	1
Hsu, C	1
Cheng, AL	1
Alter, M	1
Schenck, F	1
Satzger, I	1
Völker, B	1
Kapp, A	1
Yoon, DH	1
Ryoo, BY	1
Ryu, MH	1
Lee, SG	1
Hwang, S	1
Suh, DJ	1
Lee, HC	1
Kim, TW	1
Ahn, CS	1
Kim, KH	1
Moon, DB	1
Tanabe, K	1
Amoh, Y	1
Mii, S	1
Eto, H	1
Iwamura, M	1
Katsuoka, K	1
Wollenberg, A	1
Staehler, M	2
Eames, T	1
Laquer, V	1
Saedi, N	1
Dann, F	1
Kelly, K	1
Hull, D	2
Armstrong, C	1
Reig, M	1
Matilla, A	1
Bustamante, J	1
Castells, L	1
de La Mata, M	1
Delgado, M	1
Moreno, JM	1
Forner, A	1
Varela, M	1
Franck, N	1
Barete, S	1
Moguelet, P	1
Blanchet, B	1
Carlotti, A	1
Ropert, S	1
Avril, MF	1
Francès, C	1
Billemont, B	1
Goldwasser, F	1
Bednaríková, D	1
Kocák, I	1
Donaldson, MR	1
Stetson, CL	1
Smith, JL	1
Liang, CP	1
Yang, CS	1
Shen, JL	1
Chen, YJ	1
Cuesta, L	1
Betlloch, I	1
Toledo, F	1
Latorre, N	1
Monteagudo, A	1
Edmonds, K	1
Spencer-Shaw, A	1
Koldenhof, J	1
Chrysou, M	1
Boers-Doets, C	1
Molassiotis, A	1
Paz, C	1
Querfeld, C	1
Shea, CR	1
Weisshaupt, Ch	1
Budak, K	1
Pestalozzi, B	1
Martínez-Morán, C	1
Nájera, L	1
Ruiz-Casado, AI	1
Romero-Maté, A	1
Espinosa, P	1
Meseguer-Yebra, C	1
Córdoba, S	1
Borbujo, JM	1
Garrido-Stowhas, I	1
Cottura, E	1
Pickert, A	1
Hughes, M	1
Wells, M	1
Lewin, J	1
Farley-Loftus, R	1
Pomeranz, MK	1
Eisen, T	1
Sternberg, CN	1
Mulders, P	1
Pyle, L	1
Zbinden, S	1
Izzedine, H	1
Schmutz, JL	1
Trechot, P	1
Luo, XN	1
Lu, LG	1
Shao, PJ	1
Hu, BS	1
Li, Y	1
Yu, XY	1
He, X	1
Veraldi, S	1
Giovene, GL	1
Guerriero, C	1
Bettoli, V	1
Savvides, P	1
Nagaiah, G	1
Lavertu, P	1
Fu, P	1
Wright, JJ	1
Chapman, R	1
Wasman, J	1
Dowlati, A	1
Remick, SC	1
Strumberg, D	1
Awada, A	1
Hirte, H	1
Clark, JW	1
Seeber, S	1
Piccart, P	1
Hofstra, E	1
Voliotis, D	1
Christensen, O	1
Brueckner, A	1
Schwartz, B	1
Lacouture, ME	3
Desai, A	1
Soltani, K	1
Laumann, AE	1
Ratain, MJ	1
Stadler, WM	1
Haseke, N	1
Schöppler, G	1
Stadler, T	1
Heinemann, G	1
Stief, CG	1
Lai, SE	1
Kuzel, T	1
Akaza, H	1
Tsukamoto, T	1
Murai, M	1
Nakajima, K	1
Naito, S	1
Manchen, B	1
Beldner, M	1
Jacobson, M	1
Burges, GE	1
Dewaay, D	1
Maize, JC	1
Chaudhary, UB	1
Yang, CH	1
Lin, WC	1
Chuang, CK	1
Chang, YC	1
Pang, ST	1
Lin, YC	1
Kuo, TT	1
Hsieh, JJ	1
Chang, JW	1
Chu, D	1
Fillos, T	1
Wu, S	1
Mateus, C	1
Deslandres, M	1
Delord, JP	1
Heidary, N	1
Naik, H	1
Burgin, S	1
Heyer, G	1
Simon, M	1
Schell, H	1
Zackheim, HS	1
Ionescu, E	1
Huriez, C	1
François, P	1
Bergoend, H	1
Piette, F	1
Bessière, L	1
Bruel, P	1
Bjornstad, RT	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer[NCT00984282]	Phase 3	417 participants (Actual)	Interventional	2009-10-15	Completed
Re-validating Prophylactic Efficacy of Urea-based Cream on Sorafenib-induced Hand-foot Skin Reaction in Patients With Advanced Hepatocellular Carcinoma[NCT04568330]		129 participants (Actual)	Interventional	2014-03-21	Completed
"Evaluation of the Restorative Efficacy of the Cosmetic Product Onco-Repair vs. Placebo on Grade 2 Hand Foot Syndrome Induced by Targeted Therapies or Conventional Chemotherapy. Randomized, Multicentre, Double Blind, Controlled Study Versus Placebo."[NCT03612011]	Phase 3	72 participants (Actual)	Interventional	2018-07-12	Completed
A Prospective Cohort Study of Single Agent Memantine in Patients With Child-Pugh Score ≥ B7 Cirrhosis and Hepatocellular Carcinoma[NCT06007846]	Phase 2/Phase 3	12 participants (Anticipated)	Interventional	2023-07-31	Recruiting
Phase II Trial of BAY 43-9006 in Patients With Advanced Anaplastic Carcinoma of the Thyroid[NCT00126568]	Phase 2	20 participants (Actual)	Interventional	2005-06-30	Terminated
Phase II Study of BAY 43-9006 in Japanese Patients With Renal Cell Carcinoma[NCT00661375]	Phase 2	131 participants (Actual)	Interventional	2004-11-30	Completed
The Effect of Urea Cream on Sorafenib-associated Hand-Foot Skin Reaction in Patients With Korean Hepatocellular Carcinoma Patients: Multicenter, Prospective Randomized Double-Blind Controlled Study[NCT03212625]	Phase 4	288 participants (Actual)	Interventional	2016-01-28	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Sorafenib AUC(0-12h),ss (area under the concentration time curve from time 0 to 12 hours at steady state) was estimated from the steady state plasma concentration. (NCT00984282)
Timeframe: A single pharmacokinetic plasma sample was collected at steady state (after 14 days of uninterrupted, unmodified sorafenib dosing)

Disease Control Rate (DCR) Based on Central Assessment

Intervention	mg*h/L (Geometric Mean)
Sorafenib (Nexavar, BAY43-9006)	75.4

Disease control rate was defined as the proportion of subjects whose best response was complete response (CR), partial response (PR), or stable disease (SD). Per Response Evaluation Criteria in Solid Tumors (RECIST) criteria, CR and PR were to be confirmed by another scan at least 4 weeks later; SD had to be documented at least 4 weeks after date of randomization. CR = Disappearance of all clinical and radiological evidence of tumor (both target and no-target). PR = At least a 30% decrease in the sum of LD of target lesions taking as reference the baseline sum. SD = steady state of disease which is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. (NCT00984282)
Timeframe: From randomization of the first subject until the database cut-off (31 Aug 2012), study duration approximately three years

Duration of Response (DOR) Based on Central Assessment

Intervention	Percentage of participants (Number)
Sorafenib (Nexavar, BAY43-9006)	86.2
Placebo	74.6

Duration of response was defined as the time from the first documented objective response of PR or CR, whichever was noted earlier, to disease progression or death (if death occurred before progression was documented). CR = Disappearance of all clinical and radiological evidence of tumor (both target and no-target). PR = At least a 30% decrease in the sum of LD of target lesions taking as reference the baseline sum. (NCT00984282)
Timeframe: From randomization of the first subject until the database cut-off (31 Aug 2012), study duration approximately three years

Overall Survival (OS)

Intervention	Days (Median)
Sorafenib (Nexavar, BAY43-9006)	309
Placebo	NA

Overall survival was defined as the time (days) from date of randomization to date of death due to any cause. Subjects still alive at the time of analysis were censored at their date of last contact. Since the median value could not be estimated due to censored data, the percentage of participants who died is presented. (NCT00984282)
Timeframe: From randomization of the first subject until the database cut-off (30 AUG 2017), study duration approximately eight years

Progression-free Survival (PFS) Based on Central Assessment Incl. Clinical Progression Due to Bone Irradiation

Intervention	Percentage of participants (Number)
Sorafenib (Nexavar, BAY43-9006)	52.7
Placebo	54.8

PFS=time from randomization to first observed disease progression (radiological according to central assessment or clinical due to bone irradiation, whichever is earlier), or death due to any cause, if death occurred before progression. Progression was assessed by RECIST criteria, version 1.0, modified for bone lesions. PFS for participants without disease progression or death at the time of analysis or unblinding were censored at the last date of tumor assessment before unblinding. Participants with no tumor evaluation after baseline were censored at Day 1. PD (Progression Disease)=At least a 20% increase in sum of longest diameters (LD) of measured lesions taking as reference the smallest sum LD on study since the treatment started or the appearance of 1 or more new lesions. New lesions also constituted PD. In exceptional circumstances, unequivocal progression of a nonmeasured lesion may have been accepted as evidence of disease progression in participants with measurable disease. (NCT00984282)
Timeframe: Final analysis to be performed when approximately 267 progression-free survival events (centrally assessed) had occurred, study duration approximately three years

Response Rate Based on Central Assessment

Intervention	Days (Median)
Sorafenib (Nexavar, BAY43-9006)	329
Placebo	175

Response rate was defined as the proportion of subjects whose best response was CR or PR. Per RECIST, CR and PR was to be confirmed by another scan at least 4 weeks later. CR = Disappearance of all clinical and radiological evidence of tumor (both target and no-target). PR = At least a 30% decrease in the sum of LD of target lesions taking as reference the baseline sum. (NCT00984282)
Timeframe: From randomization of the first subject until the database cut-off (31 Aug 2012), study duration approximately three years

Time to Progression (TTP) Based on Central Assessment Incl. Clinical Progression Due to Bone Irradiation

Intervention	Percentage of participants (Number)
Sorafenib (Nexavar, BAY43-9006)	12.24
Placebo	0.5

Time to progression was defined at the time (days) from randomization to progression (based on central assessment [radiological and clinical progression due to bone irradiation]) (NCT00984282)
Timeframe: From randomization of the first subject until the database cut-off (31 Aug 2012), study duration approximately three years

Maximum Percent Reduction in Target Lesion Size Based on Central Assessment

Intervention	Days (Median)
Sorafenib (Nexavar, BAY43-9006)	337
Placebo	175

The magnitude of change from baseline in target lesion size in evaluable participants with scans was determined. (NCT00984282)
Timeframe: From randomization of the first subject until the database cut-off (31 Aug 2012), study duration approximately three years

Number of Participants That Experienced Adverse Events to Characterize the Safety Profile of BAY 43-9006

Intervention	Percentage of participants (Number)
	Reduction ≥ 30%	Reduction ≥ 20% but < 30%	Reduction ≥ 10% but < 20%	Reduction > 0% but < 10%	Growth ≥ 0%	Not assessed
Placebo	1.0	1.5	3.5	21.9	62.7	9.5
Sorafenib (Nexavar, BAY43-9006)	17.3	15.3	22.4	22.4	12.8	9.7

The safety and toxicity profile of BAY 43-9006 as measured by toxicity grades of adverse events. (NCT00126568)
Timeframe: 27 months

Overall Survival Was Measured From the Date of Outset of Treatment to the Date of Death.

Progression Free Survival Was Measured From the Date of Outset of Treatment to the Date of Disease Progression.

Number of Patients With Response to Treatment Measured by RECIST Criteria

Intervention	Participants (Count of Participants)
Treatment (Sorafenib Tosylate)	20

Intervention	months (Median)
BAY 43-9006	3.9

Intervention	months (Median)
BAY 43-9006	1.9

Response evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) Committee. The patient's best response depends on the achievement of measurement and confirmation criteria of Complete Response (CR), Stable Disease (SD), Partial Response (PR) or Progressive Disease (PD). Measurable lesions are defined as those that can be accurately measured in at least one dimension (longest diameter to be recorded) as >20 mm with conventional techniques (CT, MRI, x-ray) or as >10 mm with spiral CT scan. (NCT00126568)
Timeframe: at 6 months after treatment

Article	Year
Risk of mucocutaneous toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis. Expert review of anticancer therapy, 2014, Volume: 14, Issue:6 Topics: Alopecia; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as T	2014
Antiangiogenic agents and the skin: cutaneous adverse effects of sorafenib, sunitinib, and bevacizumab. Actas dermo-sifiliograficas, 2014, Volume: 105, Issue:10 Topics: Administration, Cutaneous; Angiogenesis Inhibitors; Antineoplastic Agents; Bevacizumab; Drug Eruptio	2014
Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology, 2009, Volume: 77, Issue:5 Topics: Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Erythema; Foot Dermatoses; Hand Dermatoses	2009
Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology, 2009, Volume: 77, Issue:5 Topics: Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Erythema; Foot Dermatoses; Hand Dermatoses	2009
Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology, 2009, Volume: 77, Issue:5 Topics: Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Erythema; Foot Dermatoses; Hand Dermatoses	2009
Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology, 2009, Volume: 77, Issue:5 Topics: Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Erythema; Foot Dermatoses; Hand Dermatoses	2009
Review article: the management of hepatocellular carcinoma. Alimentary pharmacology & therapeutics, 2010, Feb-15, Volume: 31, Issue:4 Topics: Ablation Techniques; Adult; Antineoplastic Agents; Asian People; Benzenesulfonates; Biopsy; Black Pe	2010
Management of vascular endothelial growth factor and multikinase inhibitor side effects. Clinical journal of oncology nursing, 2009, Volume: 13 Suppl Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl	2009
The hand-foot-syndrome associated with medical tumor therapy - classification and management. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2010, Volume: 8, Issue:9 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Dermatolog	2010
[Cutaneous side effects of the multikinase inhibitors sorafenib and sunitinib]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2010, Volume: 61, Issue:8 Topics: Antineoplastic Agents; Benzenesulfonates; Drug Delivery Systems; Drug Eruptions; Humans; Indoles; Ne	2010
[Hand-foot syndrome after administration of tyrosinkinase inhibitors]. Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2010, Volume: 23, Issue:5 Topics: Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Foot Dermatoses; Hand Dermatoses; Humans;	2010
Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group. European journal of oncology nursing : the official journal of European Oncology Nursing Society, 2012, Volume: 16, Issue:2 Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Clinical	2012
[Dermatologic side effects induced by new angiogenesis inhibitors]. Bulletin du cancer, 2011, Volume: 98, Issue:10 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Drug Eru	2011
Targeted therapies for renal cell carcinoma: review of adverse event management strategies. Journal of the National Cancer Institute, 2012, Jan-18, Volume: 104, Issue:2 Topics: Anorexia; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemothe	2012
Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome? European journal of cancer (Oxford, England : 1990), 2006, Volume: 42, Issue:4 Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Clinical Tr	2006
[Managing the side effects of angiogenetic inhibitors in metastatic renal cell carcinoma]. Der Urologe. Ausg. A, 2006, Volume: 45, Issue:10 Topics: Adult; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Drug Eruptions; Female; Ga	2006
[Cutaneous side effects of antiangiogenic agents]. Bulletin du cancer, 2007, Volume: 94 Spec No Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonate	2007
Sorafenib: a promising new targeted therapy for renal cell carcinoma. Clinical journal of oncology nursing, 2007, Volume: 11, Issue:5 Topics: Administration, Oral; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Diarrhea; Dru	2007
Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta oncologica (Stockholm, Sweden), 2008, Volume: 47, Issue:2 Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Drug Eruptions	2008
[Cutaneous side effects of sorafenib and sunitinib]. Annales de dermatologie et de venereologie, 2008, Volume: 135, Issue:2 Topics: Acrodermatitis; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; H	2008
[Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitors]. Annales de dermatologie et de venereologie, 2008, Volume: Spec No 1 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A	2008
Chemotherapeutic agents and the skin: An update. Journal of the American Academy of Dermatology, 2008, Volume: 58, Issue:4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites; Antineoplastic Agents; B	2008

Article	Year
Sorafenib in patients with refractory or recurrent multiple myeloma. Hematological oncology, 2013, Volume: 31, Issue:4 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera	2013
Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha-2b in metastatic melanoma (phase II DeCOG trial). Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2013, Volume: 11, Issue:9 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Causality; Comorbidity; Drug Eruptions; Female	2013
Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer. Endocrine-related cancer, 2015, Volume: 22, Issue:6 Topics: Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Aged; Antineoplastic Agents; Carcinoma, Papillary; D	2015
A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact. European journal of cancer (Oxford, England : 1990), 2016, Volume: 69 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Adenoid Cystic; Carcinoma, Mucoepider	2016
Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Archives of dermatology, 2008, Volume: 144, Issue:7 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell;	2008
Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. British journal of cancer, 2010, Jan-05, Volume: 102, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Bile Duct Neoplasms; Bilia	2010
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. Journal of hepatology, 2010, Volume: 53, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Benzenesul	2010
Efficacy and tolerability of topical 0.2% Myrtacine® and 4% vitamin PP for prevention and treatment of retinoid dermatitis in patients with mild to moderate acne. Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia, 2012, Volume: 147, Issue:5 Topics: Acne Vulgaris; Administration, Topical; Adolescent; Adult; Anti-Inflammatory Agents; Child; Drug Com	2012
Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. Thyroid : official journal of the American Thyroid Association, 2013, Volume: 23, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Drug Eruptions; Drug Resistance, Multiple; Drug Resis	2013
Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Japanese journal of clinical oncology, 2007, Volume: 37, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Di	2007
Topical 6-aminonicotinamide plus oral niacinamide therapy for psoriasis. Archives of dermatology, 1978, Volume: 114, Issue:11 Topics: 6-Aminonicotinamide; Administration, Topical; Aged; Animals; Anti-Inflammatory Agents; Clinical Tria	1978

Article	Year
Nodular-cystic eruption in course of sorafenib administration for hepatocarcinoma: An unconventional skin reaction requiring unconventional treatment. International journal of immunopathology and pharmacology, 2017, Volume: 30, Issue:3 Topics: Aminolevulinic Acid; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Eruptions; Humans; Liver	2017
Sorafenib stimulates human skin type mast cell degranulation and maturation. Journal of dermatological science, 2017, Volume: 88, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Apoptosis; Biopsy; Cell Count	2017
Multikinase inhibitor-associated hand-foot skin reaction as a predictor of outcomes in patients with hepatocellular carcinoma treated with sorafenib. World journal of gastroenterology, 2018, Jul-28, Volume: 24, Issue:28 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Eruptions; Female; F	2018
Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma. Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Carcinoma, Hepatocellular;	2013
Sorafenib induced eruptive melanocytic lesions. Dermatology online journal, 2013, May-15, Volume: 19, Issue:5 Topics: Antineoplastic Agents; Brachytherapy; Carcinoma, Renal Cell; Drug Eruptions; Fatal Outcome; Humans;	2013
Sorafenib and sunitinib for elderly patients with renal cell carcinoma. Journal of geriatric oncology, 2013, Volume: 4, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Asthenia; Carcinoma, Renal Cell; Disease-Free Surviv	2013
Acne inversa-like lesions associated with the multi-kinase inhibitor sorafenib. Clinical and experimental dermatology, 2014, Volume: 39, Issue:2 Topics: Aged; Antineoplastic Agents; Drug Eruptions; Hidradenitis Suppurativa; Humans; Leg Dermatoses; Male;	2014
Perforating folliculitis-like reaction related to sorafenib. Cutis, 2014, Volume: 93, Issue:1 Topics: Antineoplastic Agents; Drug Eruptions; Folliculitis; Humans; Male; Middle Aged; Niacinamide; Phenylu	2014
Hand, foot and scrotal blisters in a patient with cancer receiving oral chemotherapy. BMJ case reports, 2014, May-19, Volume: 2014 Topics: Administration, Oral; Administration, Topical; Adrenal Cortex Hormones; Aged; Blister; Carcinoma, He	2014
Sorafenib-associated psoriasiform eruption in a patient with hepatocellular carcinoma. Journal of drugs in dermatology : JDD, 2014, Volume: 13, Issue:8 Topics: Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Eruptions; Humans	2014
Delayed onset perforating folliculitis associated with sorafenib. The Australasian journal of dermatology, 2014, Volume: 55, Issue:3 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Drug Eruptions; Folliculitis; Humans; Kidney Neoplasms	2014
Sorafenib-Induced Eruption Mimicking Erythema Multiforme. JAMA dermatology, 2016, Volume: 152, Issue:2 Topics: Aged; Antineoplastic Agents; Drug Eruptions; Erythema Multiforme; Humans; Male; Niacinamide; Phenylu	2016
Widespread morbilliform rash due to sorafenib or vemurafenib treatment for advanced cancer; experience of a tertiary dermato-oncology clinic. International journal of dermatology, 2016, Volume: 55, Issue:4 Topics: Aged; Antineoplastic Agents; Drug Eruptions; Exanthema; Female; Humans; Indoles; Male; Middle Aged;	2016
Efficacy and Tolerability of a Skin Brightening/Anti-Aging Cosmeceutical Containing Retinol 0.5%, Niacinamide, Hexylresorcinol, and Resveratrol. Journal of drugs in dermatology : JDD, 2016, Jul-01, Volume: 15, Issue:7 Topics: Administration, Cutaneous; Cosmeceuticals; Drug Combinations; Drug Eruptions; Female; Hexylresorcino	2016
A case report: delayed high fever and maculopapules during Sorafenib treatment of ectopic hepatocellular carcinoma. BMC cancer, 2016, 07-27, Volume: 16 Topics: Carcinoma, Hepatocellular; Drug Eruptions; Fever; Humans; Liver Neoplasms; Male; Middle Aged; Niacin	2016
Sorafenib-induced eruptive melanocytic lesions. Archives of dermatology, 2008, Volume: 144, Issue:6 Topics: Administration, Oral; Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Diagn	2008
Localized palmar-plantar epidermal hyperplasia associated with use of sorafenib. Clinical drug investigation, 2008, Volume: 28, Issue:12 Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Eruptions; Erythema; Humans; K	2008
Generalised erythematous skin eruptions induced by sorafenib: cutaneous toxicity and treatment outcome. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2008, Volume: 10, Issue:12 Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dermatitis, Exfoliative; Drug Erupt	2008
Cutaneous drug eruptions induced by sorafenib: a case series. Journal of drugs in dermatology : JDD, 2008, Volume: 7, Issue:9 Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Erythema; Female; Humans; Mid	2008
Perforating folliculitis, angioedema, hand-foot syndrome--multiple cutaneous side effects in a patient treated with sorafenib. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2009, Volume: 7, Issue:5 Topics: Aged; Angioedema; Antineoplastic Agents; Benzenesulfonates; Diagnosis, Differential; Drug Eruptions;	2009
Tyrosine kinase inhibitors in advanced renal cell carcinoma: the evolving treatment paradigm. Clinical genitourinary cancer, 2009, Volume: 7, Issue:1 Topics: Benzenesulfonates; Carcinoma, Renal Cell; Drug Eruptions; Foot Diseases; Hand Dermatoses; Humans; In	2009
Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clinical genitourinary cancer, 2009, Volume: 7, Issue:1 Topics: Aged; Benzenesulfonates; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Drug Eruptions; Female; Hu	2009
[Hand-foot syndrome and sorafenib]. Bulletin du cancer, 2009, Volume: 96, Issue:2 Topics: Benzenesulfonates; Dermatology; Drug Eruptions; Foot Dermatoses; Hand Dermatoses; Humans; Kidney Neo	2009
Erythema multiforme induced by sorafenib. Clinical and experimental dermatology, 2009, Volume: 34, Issue:7 Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Eruptions; Erythema Mul	2009
Localized dyskeratotic plaque with milia associated with sorafenib. Journal of drugs in dermatology : JDD, 2009, Volume: 8, Issue:6 Topics: Acantholysis; Benzenesulfonates; Carcinoma, Hepatocellular; Diabetes Mellitus; Drug Eruptions; Hepat	2009
Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. The British journal of dermatology, 2009, Volume: 161, Issue:5 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents; Benzenesulfon	2009
Array of cutaneous adverse effects associated with sorafenib. Journal of the American Academy of Dermatology, 2009, Volume: 61, Issue:2 Topics: Benzenesulfonates; Biopsy, Needle; Cohort Studies; Dose-Response Relationship, Drug; Drug Administra	2009
Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma. American journal of clinical oncology, 2010, Volume: 33, Issue:3 Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates	2010
[Palmoplantar cutaneous reaction to sorafenib]. Actas dermo-sifiliograficas, 2009, Volume: 100, Issue:8 Topics: Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Foot Dermatoses; Hand Dermatoses; Humans;	2009
Lack of association between excretion of sorafenib in sweat and hand-foot skin reaction. Pharmacotherapy, 2010, Volume: 30, Issue:1 Topics: Antineoplastic Agents; Benzenesulfonates; Chromatography, High Pressure Liquid; Drug Eruptions; Fema	2010
Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. The oncologist, 2010, Volume: 15, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular;	2010
Sorafenib-induced psoriasiform eruption in a patient with metastatic thyroid carcinoma. Journal of drugs in dermatology : JDD, 2010, Volume: 9, Issue:2 Topics: Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Humans; Male; Middle Aged; Neoplasm Metast	2010
Sorafenib for recurrent hepatocellular carcinoma after liver transplantation. Japanese journal of clinical oncology, 2010, Volume: 40, Issue:8 Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Dru	2010
Non-pigmenting fixed drug eruption induced by sorafenib. Acta dermato-venereologica, 2010, Volume: 90, Issue:3 Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Drug Eruptions; Eryth	2010
Sorafenib-associated psoriasiform skin changes. Cutis, 2010, Volume: 85, Issue:6 Topics: Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Hand; Humans; Male; Middle Aged; Niacinami	2010
Managing patients receiving sorafenib for advanced hepatocellular carcinoma: a case study. International journal of palliative nursing, 2010, Volume: 16, Issue:5 Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Continuity of Patient Car	2010
[Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma]. Gastroenterologia y hepatologia, 2010, Volume: 33, Issue:10 Topics: Administration, Oral; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cardiovas	2010
Spiny follicular hyperkeratosis eruption: a new cutaneous adverse effect of sorafenib. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-01, Volume: 28, Issue:31 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Benzenesulfonates; Drug Eruptions; Female;	2010
Invasive squamous cell carcinoma and sorafenib in a black patient. Archives of dermatology, 2011, Volume: 147, Issue:1 Topics: Antineoplastic Agents; Benzenesulfonates; Black People; Carcinoma, Hepatocellular; Carcinoma, Squamo	2011
Sorafenib-induced acute localized exanthematous pustulosis in a patient with hepatocellular carcinoma. The British journal of dermatology, 2011, Volume: 165, Issue:2 Topics: Acute Generalized Exanthematous Pustulosis; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hep	2011
Severe sorafenib-induced hand-foot skin reaction. Dermatology online journal, 2011, May-15, Volume: 17, Issue:5 Topics: Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Carcinoma, Hepatocellular; Clobetasol; Dis	2011
Sorafenib-induced eruption resembling pityriasis rubra pilaris. Journal of the American Academy of Dermatology, 2011, Volume: 65, Issue:2 Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Biopsy, Needle; Diagnosis, Differential; Drug Erupt	2011
[Adverse effects of new oncologic therapies]. Praxis, 2011, Jul-27, Volume: 100, Issue:15 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com	2011
Interstitial granulomatous drug reaction to sorafenib. Archives of dermatology, 2011, Volume: 147, Issue:9 Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Foot Dermatoses; Granuloma; Hand Der	2011
Chloracne-like drug eruption associated with sorafenib. Journal of drugs in dermatology : JDD, 2011, Volume: 10, Issue:11 Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chloracne; Drug Eruptions; Humans;	2011
Erythema multiforme-like drug reaction to sorafenib. Journal of drugs in dermatology : JDD, 2011, Volume: 10, Issue:12 Topics: Adult; Benzenesulfonates; Diagnosis, Differential; Drug Eruptions; Erythema Multiforme; Female; Hand	2011
[Nicorandil and ulceration: a physiopathological hypothesis]. Annales de dermatologie et de venereologie, 2012, Volume: 139, Issue:3 Topics: Angina Pectoris; Drug Eruptions; Humans; NAD; NADP; Niacin; Niacinamide; Nicorandil; Skin; Skin Ulce	2012
[Relationship between sorafenib-associated hand-food skin reaction and efficacy in treatment of advanced hepatocellular carcinoma]. Zhonghua yi xue za zhi, 2012, Apr-03, Volume: 92, Issue:13 Topics: Adult; Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; D	2012
Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor. Clinical and experimental dermatology, 2006, Volume: 31, Issue:6 Topics: Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Humans; Keratosis; Male; Middle Aged; Niac	2006
Hand-foot and stump syndrome to sorafenib. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Jan-20, Volume: 25, Issue:3 Topics: Amputation Stumps; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Eruptions;	2007
Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib. The oncologist, 2007, Volume: 12, Issue:10 Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Eruptions; Erythema; Hu	2007
Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. The British journal of dermatology, 2008, Volume: 158, Issue:3 Topics: Aged; Aged, 80 and over; Benzenesulfonates; Blister; Carcinoma, Renal Cell; Drug Eruptions; Female;	2008
[Dose-dependent pellagroid skin reaction caused by carbamazepine]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 1998, Volume: 49, Issue:2 Topics: Anticonvulsants; Biopsy; Carbamazepine; Child; Diagnosis, Differential; Drug Eruptions; Epilepsy, To	1998
[Vascular erythematous reaction by administration of vitamin PP (nicotinic acid). Demonstration of a pre- and post-clinical luetic roseola]. Dermatologische Wochenschrift, 1966, Feb-19, Volume: 152, Issue:8 Topics: Drug Eruptions; Erythema; Humans; Niacinamide; Syphilis, Cutaneous	1966
[Recessive optic neuritis during lucitis due to Mederel]. Bulletin de la Societe francaise de dermatologie et de syphiligraphie, 1971, Volume: 78, Issue:1 Topics: Drug Eruptions; Gallic Acid; Humans; Ketones; Male; Middle Aged; Niacinamide; Optic Neuritis; Oxazin	1971
[Neuropsychic disorders caused by Mederel]. Bulletin de la Societe francaise de dermatologie et de syphiligraphie, 1971, Volume: 78, Issue:1 Topics: Aged; Drug Eruptions; Electroencephalography; Gallic Acid; Humans; Ketones; Male; Nervous System Dis	1971
[Pellagra during isoniazid therapy]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 1972, Mar-30, Volume: 92, Issue:9 Topics: Adult; Aged; Drug Eruptions; Female; Humans; Isoniazid; Niacinamide; Pellagra	1972

niacinamide and Dermatitis Medicamentosa